Luke Miels’ GSK buys Nuvalent for $10.6bn, adding late-stage lung cancer drugs
GSK’s new CEO commits to a major oncology bet: the $10.6bn Nuvalent deal deepens its late-stage pipeline for lung cancer.
By Mohammed Al-Shehri·· 3 min
1 briefing · “nuvalent”
GSK’s new CEO commits to a major oncology bet: the $10.6bn Nuvalent deal deepens its late-stage pipeline for lung cancer.